Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer's disease: new biomarkers for diagnosis and disease progression?  

作　　者：Rosa Maria Corbo Rita Businaro Daniela Scarabino 

机构地区：[1]Department of Biology and Biotechnology,Sapienza University,Rome,Italy [2]Department of Medico-Surgical Sciences and Biotechnologies,Sapienza University of Rome,Latina,Italy [3]CNR Institute of Molecular Biology and Pathology Rome,Italy

出　　处：《Neural Regeneration Research》2021年第7期1397-1398,共2页中国神经再生研究（英文版）

基　　金：supported by Sapienza University of Rome (2017/2018 grants allotted to RB and RMC)。

摘　　要：Alzheimer's disease and mild cognitive impairment biomarkers: Alzheimer's disease(AD) is a progressive neurodegenerative disease of advancing age.It affects around 47 million people in the world and the number is estimated to increase to 152 million by 2050.Someone develops dementia every three seconds and the current annual cost of dementia is estimated at US $1 trillion, a figure set to double by 2030(Alzheimer's Disease International, 2019).

关 键 词：ALZHEIMER IMPAIRMENT DIAGNOSIS 

分 类 号：R749.16[医药卫生—神经病学与精神病学]